DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for Change in Writing, MedComms, and Field Strategy

Digital and AI were hot topics underpinning many of the conversations at the DIA’s Medical Affairs and Scientific Communications (DIA MASC) forum I attended in March 2025, along with a focus on how we can utilize these tools to achieve impactful, engaging, and scientifically accurate communications that resonate with healthcare providers (HCPs) and patients. Along…...
Read More

Top Stories

Biopharma 2025 Trends

Biopharma Trends 2025: 3 Things to Know Right Now

The global business climate is ever-evolving, and 2025 looks...
AI in Medical Affairs & Medical Communications

Science, AI, and Human Ingenuity Converge to

Today, we're witnessing an unprecedented convergence of...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...

The Paradigm Shift from Traditional Scientific Platforms to Integrated Communications Plans

In the rapidly evolving biopharma landscape, the approach to scientific communications is undergoing a significant...
Caregivers, Clinical Trials, Global Pharma, Health Outcomes, Patient Advocacy, Patient Centricity, patient communication, Patient Engagement, Patient Inclusion, Patient Participation

Improving Health Outcomes by Empowering Patients: The Future Is Here

Empowering patients and involving them as key stakeholders in the drug development lifecycle can help...

Diversity, Equity, and Inclusion: The Fuel That Drives Business Forward

Ensuring that your organization embraces DE & I training is important for cultivating a strong...
HEOR Pharma Payers

Didactic to Dynamic: Innovative Approaches to Deeper Payer Engagements

HEOR is a fast-evolving field. Feedback from payers can influence research plans and help create...
man reviewing clinical data, current treatments, economic data, product information, and data on burden of disease

HEOR in 2022: The Importance of Data Visualization, RWD, and Interactive Formats

Effectively communicating data in the pharmaceutical and medical community is vital to payer engagement. Learn...
diversity and inclusion

Promoting Diversity and Inclusion in Clinical Trials – New England Journal of Medicine’s New Policy

Read this update on how the New England Journal of Medicine is trying to promote...

Learn more ABOUT our company.